LANSING, Mich. - Sparrow has received none of the steroidal medication that has been the subject of various media reports in recent weeks regarding the New England Compounding Center (NECC).
However, Sparrow is one of more than 3,000 medical facilities nationwide to have received a different product distributed by NECC. Sparrow is in the process of identifying Patients who may have been given the medication. None of the NECC-manufactured medication given to Patients at Sparrow has yet been linked to any illness.
"Sparrow has no reason to believe that any of these Patients who may have received medication from NECC are at risk for illness," said Brian D. Schroeder, M.D., Senior Vice President and Chief Medical Officer of Sparrow. "We have chosen to proactively take every precaution necessary to ensure the safety, health, and wellness of our Patients. Part of that precaution is keeping our Patients informed."
If any Patients receiving letters have experienced any problems with their treatment, Sparrow recommends they contact their physician or contact Sparrow Pharmacy at 517.364.0742.
"Sparrow and our team of highly trained experts are here to help and treat any conditions that could potentially arise from this incident," Schroeder said. "We strive to deliver the best experience to everyone we serve, every time - no exceptions."
The medication that may have been produced by NECC was given intravenously, mostly to cardiovascular patients. Patients experiencing symptoms such as fever, headache, and neck stiffness and who have been notified that they may have received medication from NECC should immediately contact their primary care physician.